Vivos Inc (RDGL)

[bdvest]

The share with the most potential is RDGL.

https://www.iex.nl/Forum/Topic/1356083/Koffiekamer_OTC-fonds-RDGL.aspx
needed google translation into following

It is listed on the American OTC.
The price is now about 0.014 dollar.
They will soon present a product that treats certain types of cancer. Potential here is infinitely large ...


The strategic market sector of Vivos Inc. is therapeutic isotope applications. Currently, the Company is engaged in the development of RadioGel ™, a Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.

The company is engaging the FDA for permission to use RadioGel ™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel ™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness of different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can start to generate revenues through the sale of RadioGel ™ to private animal clinics.

The Company currently is outsourcing material aspects of manufacturing of its products in the United States and intends to enter into licensing arrangements outside the United States for the manufacturing and distribution of RadioGel ™ in other countries.

What is RadioGel ™?

RadioGel ™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor. This hydrogel is a liquid temperature below the body temperature, but starts to harden, when the temperature increases to normal body temperature, locking the particles in place. The particles emit a high concentration and contained irradiation to kill the tumor. The beta radiation has a short penetration distance, so there is minimal collateral damage to healthy tissues outside of the injected area.
RadioGel ™ also has a short half-life - delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other treatment options requiring up to 6 weeks or more to a complete course of radiation therapy. This is an outpatient treatment of the patient and the patient can go home with no risk to family members.